- Short-term treatment of refractory congestive heart failure
- Available as a colourless to pale yellow solution (1 mg/mL)
- Store at room temperature, protect from freezing
- Diluted to 100 mcg/mL in D5W or NS, stable 14 days room temp or refrigerated
- Diluted to 400 mcg/mL with D5W, NS or RL, stable 14 days at room temp
- Solutions Compatible: D5W, 0.9% NaCl, 0.45% NaCl, ringer's lactate
- Additives/Above Cassette Compatible: atropine, calcium chloride, digoxin, epinephrine, morphine, propanolol, sodium bicarbonate, verapamil
- Y-site Compatible: acyclovir, amikacin, amino acids/dextrose, amiodarone, ampicillin, cefuroxime, ciprofloxacin, clindamycin, dexamethasone, dobutamine, dopamine, fentanyl, hydromorphone, lidocaine, lorazepam, KCl, meropenem, methylprednisolone sodium succinate, metronidazole, nitroglycerin, norepinephrine, piperacillin, propofol, propranolol, SMOF lipid 20%, vancomycin
- Incompatible: fat emulsion (Intralipid 20%), furosemide, imipenem-cilastatin sodium, procainamide
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
SC | NO |
IM | NO |
IV Direct |
NO |
IV Intermittent Infusion |
YES |
IV Continuous Infusion |
YES |
Click here to access SDC Drug Infusion Sheet
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric:
- Loading dose: 50 mcg/kg IV followed by a 0.5 mcg/kg/minute IV infusion
- Range 0.25-0.75 mcg/kg/minute
- Maximum: 1.13 mg/kg/day
Adolescent/Adult:
- Loading dose: 50 mcg/kg IV followed by a 0.375-0.75 mcg/kg/minute IV infusion
- Maximum: 1.13 mg/kg/day
DOSAGE ADJUSTMENT IN RENAL IMPAIRMENT:
CrCl (mL/minute) |
Infusion Rate (mcg/kg/minute) |
50 |
0.43 |
40 |
0.38 |
30 |
0.33 |
20 |
0.28 |
10 |
0.23 |
5 |
0.20 |
- Tachyarrhythmias, hypotension, angina/chest pain
- Headache
- Hypokalemia
- Thrombocytopenia
- Monitor BP, HR, cardiac output, CI, CVP, SVR, PVR, EKG, serum electrolytes, CrCl, platelet count, renal function; clinical signs and symptoms of congestive heart failure
- Decrease infusion rate if significant hypotension occurs
- Avoid use in patients with severe obstructive aortic or pulmonic valvular disease
- Use with caution in patients with a history of ventricular arrhythmias, atrial fibrillation, atrial flutter, impaired renal function
- There are no controlled trials using milrinone infusions for >48 hours
- Onset: 5-15 minutes